Drug Trial Radar · NCT03823287
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
Last checked: Nov 20, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
671
Actual
Start
Feb 19, 2019
Primary completion
Oct 26, 2020
Study completion Jan 18, 2022
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with neovascular age-related macular degeneration (nAMD).
Conditions
- Wet Macular Degeneration
Interventions
FaricimabDrug
Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
AfliberceptDrug
Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
Sham ProcedureProcedure
The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in both treatments arms at applicable visits to maintain masking.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in BCVA in the Study Eye Averaged Over Weeks 40, 44, and 48Time frame: From Baseline through Week 48
Locations
161 sites in 15 countries. Site status is shown where the registry gives one.
Retinal Research Institute, LLC
Phoenix, Arizona
Barnet Dulaney Perkins Eye Center
Phoenix, Arizona
Retina Associates Southwest PC
Tucson, Arizona
Retinal Diagnostic Center
Campbell, California
The Retina Partners
Encino, California
Jacobs Retina center at the Shiley eye Institute UCSD
La Jolla, California
South Coast Retina Center
Long Beach, California
Southern CA Desert Retina Cons
Palm Desert, California
California Eye Specialists Medical group Inc.
Pasadena, California
Retina Consultants, San Diego
Poway, California
Retina Consultants of Southern California
Redlands, California
University of California, Davis, Eye Center
Sacramento, California
Retina Consultants of Southern
Colorado Springs, Colorado
Retina Group of New England
New London, Connecticut
Rand Eye
Deerfield Beach, Florida
Florida Eye Associates
Melbourne, Florida
Retina Specialty Institute
Pensacola, Florida
Fort Lauderdale Eye Institute
Plantation, Florida
Retina Vitreous Assoc of FL
St. Petersburg, Florida
Northwestern Medical Group/Northwestern University
Chicago, Illinois
Retina Associates
Lenexa, Kansas
Johns Hopkins Med
Baltimore, Maryland
Retina Group of Washington
Chevy Chase, Maryland
Tufts Medical Center
Boston, Massachusetts
Associated Retinal Consultants
Grand Rapids, Michigan
Midwest Vision Research Foundation
Chesterfield, Missouri
Retina Associates of St. Louis
Florissant, Missouri
Sierra Eye Associates
Reno, Nevada
NJ Retina
Edison, New Jersey
Retina Associates of NJ
Teaneck, New Jersey
Long Is. Vitreoretinal Consult
Great Neck, New York
Ophthalmic Cons of Long Island
Oceanside, New York
Retina Assoc of Western NY
Rochester, New York
The Retina Consultants
Slingerlands, New York
Retina Vit Surgeons/Central NY
Syracuse, New York
Western Carolina Retinal Associate PA
Asheville, North Carolina
Char Eye Ear &Throat Assoc
Charlotte, North Carolina
Graystone Eye
Hickory, North Carolina
Carolina Eye Associates
Southern Pines, North Carolina
Cincinnati Eye Institute
Cincinnati, Ohio
Showing 40 of 161 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.